We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cumberland Pharmaceutical Inc | NASDAQ:CPIX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.42 | 1.39 | 2.28 | 0 | 09:05:34 |
1. Name and Address of Reporting Person * Young Caroline | 2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [ CPIX ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 12/1/2021 | P | 18 (1) | A | $4.14 | 14401 | D | |||
Common Stock | 12/2/2021 | P | 18 (1) | A | $3.84 | 14419 | D | |||
Common Stock | 12/3/2021 | P | 18 (1) | A | $4.47 | 14437 | D | |||
Common Stock | 12/6/2021 | P | 18 (1) | A | $4.46 | 14455 | D | |||
Common Stock | 12/7/2021 | P | 18 (1) | A | $5.61 | 14473 | D | |||
Common Stock | 12/8/2021 | P | 18 (1) | A | $6.15 | 14491 | D | |||
Common Stock | 12/9/2021 | P | 18 (1) | A | $5.81 | 14509 | D | |||
Common Stock | 12/10/2021 | P | 18 (1) | A | $4.82 | 14527 | D | |||
Common Stock | 12/13/2021 | P | 30 (1) | A | $4.36 | 14557 | D | |||
Common Stock | 12/14/2021 | P | 30 (1) | A | $4.28 | 14587 | D | |||
Common Stock | 12/15/2021 | P | 30 (1) | A | $4.29 | 14617 | D | |||
Common Stock | 12/16/2021 | P | 50 (1) | A | $4.53 | 14667 | D | |||
Common Stock | 12/17/2021 | P | 50 (1) | A | $4.17 | 14717 | D | |||
Common Stock | 12/20/2021 | P | 60 (1) | A | $4.33 | 14777 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: | |
(1) | The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021. |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Young Caroline 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 | X |
Signatures | ||
Caroline Young by /s/ John Hamm as attorney-in-fact | 1/7/2022 | |
**Signature of Reporting Person | Date |
1 Year Cumberland Pharmaceutical Chart |
1 Month Cumberland Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions